 Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Erdafitinib for Sale > Erdafitinib High quality CAS 1346242-81-6

Erdafitinib High quality CAS 1346242-81-6 buy - large image1

Erdafitinib High quality CAS 1346242-81-6 buy - image1

Erdafitinib High quality CAS 1346242-81-6 buy - image2

Erdafitinib High quality CAS 1346242-81-6 buy - image3

Erdafitinib High quality CAS 1346242-81-6

626 Inquiries

Unit Price:

$8-9/KG FOB

Get Latest Price 

CAS No.:

1346242-81-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Shanghai

Packaging:

1kg/bag;25kg/Cardboard Drum

Sample Available:

Yes

Price valid (until):

2026-11-30

Contact Supplier

 Chat Now

Xi'an Honest BioEngr Co.,Ltd.

Company Type:

Trader

Location:

China

Payment Terms:

TT against copy of documents,100% TT in advance

Average Lead Time:

30 days

Qualification:

Main Products:

Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10

 Visit Store

Product Details
Seller Information
Inquiry History

Description

Product Detail

Superiority

We are the manufacturers and suppliers of API in China, and warehouse in Germany and USA of California, which can quickly and safely deliver to your address

1.High quality and competitive price.
2.Free sample for your evaluation.
3.Promptly delivery by well-reputed shipping lines.
4.Trial order is available for testing after samples.
5.We will inform you all the information at every stage in advance.
6.Packaging can gear to buyers' special request.

Our service

1. Reply your inquiry in 24 working hours.
2. Customized design is available. OEM are welcomed.
3. Exclusive and unique solution can be provided to our customer by our well-trained and professional engineers and
staff.
4. Professional factory: We are manufacturer, specializing in producing all kinds of herb extract for more than 10 years, competitive with good quantity.
5. As an honest seller, we always use superior raw material, advanced machines, skilled technicians to ensure our products to be finished in high quality and stable feature.

Shop High quality Deoxyribonucleic Acid from Salmon sperm CAS 100403-24-5-Detailed Image 1

Shop High quality Deoxyribonucleic Acid from Salmon sperm CAS 100403-24-5-Detailed Image 2

FAQ

1.: Are you a factory or trading company
We are the integration of factory and trade.

2.: How is the quality I want to test.
Before production and extraction, we will test all raw materials.Quality is our top priority.All products are strictly tested and confirmed by our QC and QA, approved by Third Party Lab in China.So you will be assured with Good Quality if you choose us. We welcome you test the product and hope to get your feedback.

3.: Can I get a Free sample
Yes,We can provide free samples.For most products we can provide you a free sample, You only need to pay for Shipping. Plesae be free to consult our salesman.
For a larger quantity, we always support you with better price, and we will have some discount in some especial days.

4. : What's your main payment method
T/T (Bank transfer), Wechat,Alipay,Credit card payment.

5. : Have you received my payment How long will it take
Generally, we can receive your payment the next day, and we will inform you as soon as we receive your payment.
After confirmation payment, we will send out package

6.:When will you sent out the goods after successful payment
Normally the order will be delivery within 1-3 days after the order confirmed, except the customized products.

7.:What modes of transportation do you have to choose
We cooperate with HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post ,sea transportation etc.
And with the SAFE SHIPPING in each country, you can receive the goods smoothly.It is fast and safe method.

8.:How long does it take to the goods arrived
It is Depending on your location:
For small order, please expect 5-7 days by DHL,UPS,TNT, FEDEX, HKEMS,Netherlands post.
For large order, please allow 5-8 days by Air, 20-35 days by Sea
At the same time, we have warehouses in Germany and California, and some orders can be sent directly from Germany or California.

9.:How is the goods packed
We usually send goods with disguise package outside and a double-layer sterile transparent bag inside.We have tried thousand of package methods, it looks serious and discreet.

10.: How can I get a discount
Our products have already given you a discount, and the price is favorable. Orders above $1,000 can enjoy 95% discount, transportation discount or additional sample products. Therefore, for larger quantities, we always support better prices.

11.: How to proceed order
Please Let me konw the product you are looking for,quantity and the destination country wihch help me to give you a right price;
After you confirm all details of order, pay money in advance and give us Shipping address.We arrange the shipment at first time after receive payment and offer after-sales service after you receive parcel.

12.:When will I receive the shipping number Where I can check status of my order
After the goods are sent out, our staff will send you the shipping number via email, online or WhatsApp ASAP.You can also check the status online on 17track.

13.:Is a signature required for the shipping?
Our shipping method requires no signature from your side upon delivery.

ECHEMI Editorial Reference

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

Basic Info

Product Name:

Erdafitinib

Other Name:

1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

CAS No.:

1346242-81-6

Molecular Formula:

C25H30N6O2

InChIKeys:

InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

Molecular Weight:

446.54

Exact Mass:

446.54

UNII:

890E37NHMV

NCI Thesaurus Code:

C103273

ATC Code:

L - Antineoplastic and immunomodulating agents

Categories:

Bulk Drug Intermediates

Characteristics

PSA:

77.3

XLogP3:

3.2

Density:

1.2±0.1 g/cm3

Flash Point:

354.4±31.5 °C

Refractive Index:

1.618

Water Solubility:

<1 mg/mL

Research

Class:

Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

Status:

Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

Mechanism:

Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

EC50 (Fgfr1 Ic50):

1.2 nM

EC50 (Fgfr3 Ic50):

3.0 nM

EC50 (Fgfr2 Ic50):

2.5 nM

EC50 (Fgfr4 Ic50):

5.7 nM

EC50 (Vegfr2 Ic50):

36.8 nM (approximately 30-fold selectivity vs FGFR1)

Source:

Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

Clinical Development:

NCT02365597; NCT03390504

FDA:

Balversa (approved 2019-04-12)

References

ChEMBL:

DrugBank:

KEGG DRUG:

PubChem:

Literature:

FDA: Approval announcement 2024-01-19; FDA: BALVERSA label (NDA 212018, BLC2001); NEJM: Loriot et al. (2023) — THOR Cohort 1; NEJM: Loriot et al. (2019) — BLC2001; Mol Cancer Ther: Perera et al. (2017) — discovery pharmacology

Disclaimer:

Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

See More Erdafitinib Properties 

Hazard Identification

Classification of the substance or mixture

Acute toxicity - Category 4, Oral

Skin sensitization, Sub-category 1B

Serious eye damage, Category 1

Reproductive toxicity, Category 2

Specific target organ toxicity â repeated exposure, Category 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Danger
Hazard statement(s)	H302 Harmful if swallowed H317 May cause an allergic skin reaction H318 Causes serious eye damage H361 Suspected of damaging fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/... P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response	P301+P317 IF SWALLOWED: Get medical help. P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P333+P317 If skin irritation or rash occurs: Get medical help. P321 Specific treatment (see ... on this label). P362+P364 Take off contaminated clothing and wash it before reuse. P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P317 Get medical help. P318 IF exposed or concerned, get medical advice. P319 Get medical help if you feel unwell.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Erdafitinib Safety Data Sheet 

Seller Information

Business Type:
Trader

Main Products:
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10

Location:
XINYUAN DADUHUI PHASE 1, NO.258 TAOYUAN NORTH ROAD, LIANHU DISTRICT, XI 'AN , SHAANXI CHINA

Payment Terms:
TT against copy of documents,100% TT in advance

Average lead Time:
30 days

Total Annual Revenue:
$2.5 million-$5 million

Total Employees:
11-50

Year of Establishment:
2023

Company Profile

Inquiry History

626 Inquiries

Country	Product	Purchase Quantity	Date Posted
Germany	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 25, 2026
Vietnam	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 18, 2026
United States	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 26, 2026
Australia	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 14, 2026
Poland	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 28, 2026
United Kingdom	Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6	1 MT	Sep 4, 2026
United States	Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder	1 G	Sep 3, 2026
Canada	Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6	1 G	Sep 15, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Sep 1, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Aug 25, 2026
United States	Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price	3 MT	Jul 5, 2026
Australia	Erdafitinib	1 KG	Oct 16, 2026
Canada	Erdafitinib	1 G	Oct 12, 2026
Australia	Erdafitinib	500 MG	Sep 16, 2026
Australia	Erdafitinib	1 G	Jul 18, 2026
Germany	Erdafitinib	500 MG	Jul 28, 2026
Spain	Erdafitinib	1 G	Sep 25, 2026
Cyprus	Erdafitinib	1 G	Jul 22, 2026
Germany	Erdafitinib	5 G	Sep 17, 2026
Bulgaria	Erdafitinib	500 MG	Jun 18, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Raw Erdafitinib API, CAS 1346242-81-6	Pharmaceutical Grade/99	$1/G FOB	PERBAVI SPRL	Inquiry
Erdafitinib high pure 99% raw powder CAS 1346242-81-6	Pharmaceutical Grade/99	$1/G FOB	Hubei Meisang Trading Co.,Ltd	Inquiry
erdafitinib(1346242-81-6)	Industrial Grade/99.5	$9900-11000/MT FOB	Xiamen Eagle Chemical Corporation	Inquiry
Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	Pharmaceutical Grade/98	$100-120/G FOB	Xi'an Horlden Bio-Tech Co., Ltd	Inquiry
High Quality Erdafitinib 99% powder 1346242-81-6-Shaanxi Dideu Medichem Co.Ltd	Chemical Grade/99	$1/G FOB	Shaanxi Dideu Medichem Co. Ltd	Inquiry

Erdafitinib High quality CAS 1346242-81-6

Product Details

Seller Information